20/12/2013 |
Cleansing Notice and Appendix 3B |
18/12/2013 |
Results of Completed CK3000 Diagnostic Study |
11/12/2013 |
$2 Million Capital Raising |
25/11/2013 |
Appendix 3B and Change of Interests of Substantial Holding |
25/11/2013 |
Change of Director’s Interest Notice – Maria Halasz |
25/11/2013 |
Cleansing Statement |
22/11/2013 |
AGM Presentation by CEO |
22/11/2013 |
Results of Meeting |
20/11/2013 |
Change in substantial holding |
18/11/2013 |
Proposed Issue of Shares |
30/10/2013 |
Release of Shares from Voluntary Escrow |
23/10/2013 |
Appendix 4C – quarterly |
21/10/2013 |
Annual Report to Shareholders |
21/10/2013 |
Notice of Annual General Meeting and Proxy Form |
18/10/2013 |
Key Antibody Patent Granted in Japan |
08/10/2013 |
Key European Patent for Anti-Midkine Antibodies Granted |
04/10/2013 |
R&D Tax refund received |
03/10/2013 |
Midkine antibodies effective in cancer |
20/09/2013 |
Cellmid Signs Major Japanese Distribution Agreement |
19/09/2013 |
Independent Valuation Report of Advangen Inc Japan |
18/09/2013 |
Cellmid CEO Presents at Brokers Meet Biotech |
10/09/2013 |
Date of Annual General Meeting |
03/09/2013 |
Change in substantial holding |
28/08/2013 |
Appendix 4E and Preliminary Final Report |
01/08/2013 |
Cellmid Received Pacific Edge Milestone Shares |
29/07/2013 |
Cellmid Collaborates on Early Diagnosis of Colorectal Cancer |
26/07/2013 |
Appendix 4C – quarterly |
22/07/2013 |
Release of Shares from Voluntary Escrow |
18/07/2013 |
Fujikura Exercises Option To License Cellmid’s Diagnostics |
16/07/2013 |
Appointment of Company Secretary |
04/07/2013 |
Change of Director’s Interest Notice |
12/06/2013 |
Change of Director’s Interest Notice |
28/05/2013 |
Settlement of Advangen Inc Acquisition Completed |
20/05/2013 |
Cellmid News |
08/05/2013 |
Advangen Acquisition |
08/05/2013 |
CEO Presentation |
30/04/2013 |
Change of Company Address |
22/04/2013 |
Appendix 4C – quarterly |
08/04/2013 |
Resignation of Company Secretary |
26/03/2013 |
Cellmid Diagnostic Licenses Update |
22/03/2013 |
Appendix 3B |
13/03/2013 |
Cellmid Completes $2M Placement |
04/03/2013 |
Change in Director’s Interest – M Halasz |
19/02/2013 |
Change in Director’s Interest – M Rogers |
11/02/2013 |
Cellmid Signs Midkine Diagnostic Agreement |
29/01/2013 |
Appendix 4C Quarterly report |
29/01/2013 |
Cellmid News |
23/01/2013 |
Positive Data in Midkine Antibody Study in Kidney Disease |
21/01/2013 |
European Patent Allowed for Treating Vascular Occlusive Disease |
11/01/2013 |
Change in Director’s Interest – M Halasz |
07/01/2013 |
Change in Director’s Interest – M Halasz |